In the realm of immunity, inhibiting glycolysis in breast cancer patients via the CEBPB pathway impedes G‐CSF and GM‐CSF production, reducing myeloid‐derived suppressor cells (MDSCs) and enhancing anti‐tumour immunity.39 The gene discussed is CEBPB; the disease is breast carcinoma.